

OMB APPROVAL	
OMB Number:	3235-0287
Estimated average burden hours per response:	0.5

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person* <u>Mainolfi Nello</u>			2. Issuer Name and Ticker or Trading Symbol <u>Kymera Therapeutics, Inc. [KYMR]</u>			5. Relationship of Reporting Person(s) to Issuer (Check all applicable) <input checked="" type="checkbox"/> Director 10% Owner <input checked="" type="checkbox"/> Officer (give title below) Other (specify below) Chief Executive Officer		
(Last)	(First)	(Middle)	3. Date of Earliest Transaction (Month/Day/Year) <u>10/08/2021</u>			6. Individual or Joint/Group Filing (Check Applicable Line) <input checked="" type="checkbox"/> Form filed by One Reporting Person Form filed by More than One Reporting Person		
C/O KYMERA THERAPEUTICS, INC. 200 ARSENAL YARDS BLVD., SUITE 230			4. If Amendment, Date of Original Filed (Month/Day/Year)					
(Street) <u>WATERTOWN MA 02472</u>								
(City) (State) (Zip)								

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Common Stock	10/08/2021		M		41,544	A	\$2.08	505,743	D	
Common Stock	10/08/2021		s ⁽¹⁾		21,236	D	\$55.5598 ⁽²⁾	484,507	D	
Common Stock	10/08/2021		s ⁽¹⁾		9,369	D	\$56.8247 ⁽³⁾	475,138	D	
Common Stock	10/08/2021		s ⁽¹⁾		2,078	D	\$57.2887 ⁽⁴⁾	473,060	D	
Common Stock	10/08/2021		s ⁽¹⁾		7,920	D	\$59.2756 ⁽⁵⁾	465,140	D	
Common Stock	10/08/2021		s ⁽¹⁾		670	D	\$60.3165 ⁽⁶⁾	464,470	D	
Common Stock	10/08/2021		s ⁽¹⁾		271	D	\$61.87	464,199	D	
Common Stock	10/11/2021		M		6,456	A	\$2.08	470,655	D	
Common Stock	10/11/2021		s ⁽¹⁾		5,712	D	\$53.5791 ⁽⁷⁾	464,943	D	
Common Stock	10/11/2021		s ⁽¹⁾		744	D	\$54.4979 ⁽⁸⁾	464,199	D	

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
				Code	V		Date Exercisable	Expiration Date						Amount or Number of Shares
Stock Option (Right to Buy)	\$2.08	10/08/2021		M		41,544	(9)	11/13/2029	Common Stock	41,544	\$0.00	35,181	D	
Stock Option (Right to Buy)	\$2.08	10/11/2021		M		6,456	(9)	11/13/2029	Common Stock	6,456	\$0.00	28,725	D	

Explanation of Responses:

- This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on November 6, 2020.
- The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from \$55.10 to \$56.09. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
- The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from \$56.19 to \$57.185. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
- The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from \$57.20 to \$58.14. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
- The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from \$58.90 to \$59.81. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
- The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from \$59.91 to \$60.61. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
- The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from \$53.19 to \$54.16. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
- The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from \$54.28 to \$54.60. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
- The shares underlying this stock option shall vest upon the achievement of specified performance-based milestones.

Remarks:

/s/ Bruce Jacobs, as Attorney- 10/12/2021
in-Fact

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.